Shares of Aequus Pharmaceuticals Inc. (CVE:AQS – Get Free Report) reached a new 52-week low during mid-day trading on Thursday . The company traded as low as C$0.01 and last traded at C$0.01, with a volume of 408000 shares. The stock had previously closed at C$0.02.
Aequus Pharmaceuticals Price Performance
The stock has a market cap of C$663,150.00, a price-to-earnings ratio of -0.50 and a beta of -0.02. The company has a 50 day simple moving average of C$0.01 and a 200-day simple moving average of C$0.02. The company has a current ratio of 0.07, a quick ratio of 0.46 and a debt-to-equity ratio of 138.88.
Aequus Pharmaceuticals (CVE:AQS – Get Free Report) last announced its earnings results on Thursday, August 29th. The company reported C($0.01) earnings per share (EPS) for the quarter. The company had revenue of C$0.16 million during the quarter. Research analysts expect that Aequus Pharmaceuticals Inc. will post -0.1 EPS for the current year.
About Aequus Pharmaceuticals
Aequus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada. The company markets ZIMED PF, a preservative-free bimatoprost ophthalmic solution. It also develops a range of prescription-free dry eye products under the OPTASE name; and REV-0100 for the treatment of stargardt disease.
Featured Stories
- Five stocks we like better than Aequus Pharmaceuticals
- How to Invest in Blue Chip Stocks
- Vertiv’s Cool Tech Makes Its Stock Red-Hot
- Insider Selling Explained: Can it Inform Your Investing Choices?
- MarketBeat Week in Review – 11/18 – 11/22
- What Investors Need to Know to Beat the Market
- 2 Finance Stocks With Competitive Advantages You Can’t Ignore
Receive News & Ratings for Aequus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aequus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
